





VENABLE | Fitzpatrick


December 31, 2021











FWD = Final Written Decision



Spotlight On: Rituximab

VENABLE | Fitzpatrick

December 31, 2021

Technology: Rituximab is a chimeric murine/human monoclonal antibody that is directed against the CD20 antigen. CD20 is a protein that is primarily found on the surface of immune system B cells. CD20 is involved in cell growth and differentiation.

	Genentech v. Celltrion 1:18-cv- 11553 (D.N.J.) Settled Cont'd below	Genentech v. Celltrion 1:18-cv- 00574 (D.N.J.) Settled Cont'd below	Celltrion v. Genentech 4:18-cv-00276 (N.D. Cal.) Dismissed; Appeal No. 18- 2161 Dismissed	Genentech v. Sandoz 1:17-cv-13507 (D.N.J.) Dismissed Cont'd below	Celltrion v. Genentech IPR2017-01227 Institution denied	Celltrion v. Genentech IPR2017-01230 Institution denied	Pfizer v. Genentech IPR2017- 02126 Institution denied	Boehringer Ingelheim v. Genentech IPR2015-00415 Petitioner request for adverse judgment after institution	Celltrion v. Genentech IPR2015- 01744 Petitioner dismissed prior to institution decision	Celltrion v. Genentech IPR2016-01614 FWD (no instituted claim unpatentable); Appeal 18-1924 dismissed	Pfizer v. Genentech IPR2017-01115 (Joined with IPR2016-01614) FWD (no instituted claim unpatentable); Appeal 18-1885 dismissed (settled)
6,121,428		X		X							
6,242,177		х									
6,331,415	х	х	X	x							
6,417,335		х	Х								
6,455,043		х	Х								
6,489,447	х	х	Х	x							
6,586,206		х	Х								
6,610,516	х	х	Х	х							
6,620,918	х	х	Х	х							
6,716,602		X	Х								
6,870,034				x							
7,381,560	х	x		x							
7,390,660		х	Х								
7,485,704	х	х	Х	x							
7,682,612		х	Х		х	х	х				
7,807,799	х	х	Х	х							
7,820,161	х	х	Х	x				х	х	х	х
7,923,221	x	x	x	x	Boehringer Ingelheim v. Genentech IPR2015-00417 Petitioner request for adverse judgment after institution	Celltrion v. Genentech IPR2015-01733 Petitioner dismissed prior to institution decision	Celltrion V. Genentech IPR2016- 01667 Institution denied	Pfizer v. Genentech IPR2017-01923 Settled after institution	Sandoz v. Genentech IPR2017- 02036 Institution denied	Sandoz v. Genentech IPR2017-02042 Institution denied	Celltrion v. Genentech IPR2018-01019 Joined with IPR2017-01923; Settled after institution
7,976,838	х	x	X	х	X	х	х	x	x	X	X



Spotlight On: Rituximab

VENABLE | Fitzpatrick

December 31, 2021

	Genentech v. Celltrion 1:18-cv-11553 (D.N.J.) Settled Cont'd from above	Genentech v. Celltrion 1:18-cv- 00574 (D.N.J.) Settled Cont'd from above	Celltrion v. Genentech 4:18-cv-00276 (N.D. Cal.) Dismissed; Appeal No. 18-2161 Dismissed Cont'd from above	Genentech v. Sandoz 2:17-cv-13507 (D.N.J.) Dismissed Cont'd from above	Celltrion v. Genentech IPR2017- 01229 Institution denied	Pfizer v. Biogen IPR2017- 02127 Institution denied	Boehringer Ingelheim v. Biogen IPR2015- 00418 Institution denied	Celltrion v. Biogen IPR2017-01093 Institution denied	Pfizer v. Biogen IPR2017-01166 Institution denied; Request for rehearing withdrawn	<i>Pfizer v. Biogen</i> IPR2018-00285 Settled after institution	
8,044,017		Х	X								
8,206,711	Х	х	Х	x	x	x					
8,314,225				x							
8,329,172	х	x	Х	x			Х	X	X	X	
8,357,301		x	x					Pfizer v. Biogen IPR2017-01168 FWD (All instituted claims unpatentable); Appeal 19-1364 affirmed with US, settled with Pfizer	Celltrion v. Biogen IPR2017-01095 FWD (All instituted claims unpatentable); Appeal 19-1253 dismissed as to US, settled with Celltrion	Pfizer v. Biogen IPR2018- 00186 Terminated after institution Pfizer v. Biogen IPR2018-00231 Petitioner dismissed prior to institution decision	
8,460,895		х	х		Pfizer v.	Celltrion v. Biogen IPR2017- 01094 Institution denied	Pfizer v. Biogen IPR2017- 01167 Institution denied				
8,512,983		X	X	x	Genentech IPR2018- 00086 Institution denied						Petitioner dismissed prior to institution
8,545,843	x	x	x	х	х						
8,557,244	X	х	X	x		x	Х				
8,574,869	Х	х	X	x							
8,633,302		х	х								
8,710,196		х	х	x							
8,771,988		х	Х								
8,821,873	x	x	x	х				Х			
8,822,655		x	Х								
9,047,438		х	Х								
9,080,183		х	Х								
9,296,821	х	х	Х	x					X	x	
9,428,548		х	Х								
9,428,766		х	Х								
9,487,809		х	Х								
9,504,744	х	x	X	x							X
9,714,293		х	х	х							